South Florida's Life Sciences Corridor Has a Scaling Problem

South Florida has been building a legitimate life sciences cluster for two decades, and the results are visible in the stretch between Boca Raton and Jupiter. The Scripps Research Institute campus in Jupiter — relocated from La Jolla, California in 2004 — employs hundreds of scientists working on drug discovery and basic research. The Max Planck Florida Institute for Neuroscience, also in Jupiter, is one of the few Max Planck Society outposts outside Germany. The Palm Beach Bioscience Center in Palm Beach Gardens has drawn dozens of commercial life sciences firms to a county that a generation ago did not appear on most biotech investors’ maps.

Now the question is whether the operations behind that science can scale with it.

Lab procurement in the life sciences is structurally different from purchasing in most other industries, which is part of why it has stayed broken for so long. A manufacturer ordering steel or a retailer restocking inventory can build supplier relationships over years, negotiate volume contracts, and run predictable purchasing cycles. Life sciences doesn’t work that way. Research protocols change mid-experiment. New assays require reagents that didn’t exist six months ago. The antibody that works in one cell line may not work in another, and finding an alternative means sourcing from a different supplier — with a different catalog, a different ordering portal, and a different compliance documentation trail.

The supplier base itself is fragmented by design. There is no life sciences equivalent of a general merchandise distributor. Specialized reagents come from specialized manufacturers, and a single lab running multiple research programs may maintain active purchasing relationships with 50, 80, or more vendors simultaneously. Each relationship means separate invoicing, separate lot tracking, and separate vendor qualification — because in a GMP-adjacent environment, onboarding a new supplier isn’t a 10-minute signup. It can take weeks, involving legal, compliance, and finance sign-off before a single purchase order gets issued.

Early-stage companies feel this most acutely. A founding team at a 15-person Boca Raton startup doesn’t typically have a procurement department. Researchers buy their own supplies. Finance reconciles the chaos later. Nobody has bandwidth to build the infrastructure that would make the whole system run cleanly, so the workarounds calcify into standard operating procedure. As the company grows — from 15 people to 50, from one research program to three — the vendor relationships multiply, the purchase orders pile up, and suddenly a company burning through $800,000 a month in runway is dedicating meaningful hours of that spend to paperwork.

Industry data on this is consistent and not flattering. A recent analysis of how the problem plays out across the biotech sector found that 89 percent of laboratory professionals report experiments have been delayed by backorders or supply disruptions, and 67 percent say they would not recommend their current ordering process to a colleague. Procurement teams at mid-size biotechs spend more than 20 hours per week on order management alone. In an industry where Deloitte estimates the average drug costs $2.3 billion to bring to market, the hours lost to vendor follow-ups and invoice reconciliation carry a real price tag that shows up — eventually — in development timelines and burn rates.

This is where South Florida’s cluster faces a structural disadvantage relative to more established hubs. The Northeast corridor — Boston, New Jersey, Connecticut — has decades of large pharmaceutical operations behind it. Companies like Merck, Johnson & Johnson, and Bristol-Myers Squibb built mature procurement infrastructure over generations, and that institutional knowledge passed down to the spinouts and startups that grew up around them. The procurement muscle is embedded in the regional ecosystem. South Florida’s cluster is younger and earlier-stage, without that inheritance. The infrastructure that the Northeast takes for granted here largely has to be built from scratch by companies that are simultaneously trying to advance their science.

The tools to do it are available. Life sciences-specific lab management software and procurement platforms — ZAGENO is among the better-documented examples — have produced measurable results where they’ve been adopted. One Massachusetts biotech that consolidated from 98 separate vendor relationships to a single procurement platform recovered more than 250 hours of researcher time and saved over $200,000 in staff costs in its first year. PwC projects that 70 percent of life sciences procurement will be digitalized by 2027, a timeline that tracks with where adoption is already heading in the more mature clusters.

For South Florida’s emerging corridor, the gap is not scientific. The research happening in Jupiter and across Palm Beach County competes with anything coming out of Cambridge or Kendall Square. The gap is operational — and closing it is the kind of unglamorous infrastructure work that tends to determine, years later, which regional clusters actually scaled and which ones stalled out.